340 related articles for article (PubMed ID: 35026352)
21. CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
Wang D; Zhang F; Gao G
Cell; 2020 Apr; 181(1):136-150. PubMed ID: 32243786
[TBL] [Abstract][Full Text] [Related]
22. Clinical progress in genome-editing technology and in vivo delivery techniques.
Khirallah J; Eimbinder M; Li Y; Xu Q
Trends Genet; 2023 Mar; 39(3):208-216. PubMed ID: 36669950
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
24. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
[TBL] [Abstract][Full Text] [Related]
25. Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants.
Alghuthaymi MA; Ahmad A; Khan Z; Khan SH; Ahmed FK; Faiz S; Nepovimova E; Kuča K; Abd-Elsalam KA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299081
[TBL] [Abstract][Full Text] [Related]
26. Clinical trials and promising preclinical applications of CRISPR/Cas gene editing.
Çerçi B; Uzay IA; Kara MK; Dinçer P
Life Sci; 2023 Jan; 312():121204. PubMed ID: 36403643
[TBL] [Abstract][Full Text] [Related]
27. Recognizing CRISPR as the new age disease-modifying drug: Strategies to bioengineer CRISPR/Cas for direct in vivo delivery.
Thevendran R; Maheswaran S
Biotechnol J; 2023 Sep; 18(9):e2300077. PubMed ID: 37179485
[TBL] [Abstract][Full Text] [Related]
28. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
29. [The new generation tool for CRISPR genome editing: CRISPR/Cpf1].
Yang F; Li Y
Sheng Wu Gong Cheng Xue Bao; 2017 Mar; 33(3):361-371. PubMed ID: 28941336
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
31. CRISPR editing in biological and biomedical investigation.
Huang J; Wang Y; Zhao J
J Cell Physiol; 2018 May; 233(5):3875-3891. PubMed ID: 28786481
[TBL] [Abstract][Full Text] [Related]
32. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
33. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
Li X; Shi W; Geng LZ; Xu JP
Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas-based genome engineering in natural product discovery.
Tong Y; Weber T; Lee SY
Nat Prod Rep; 2019 Sep; 36(9):1262-1280. PubMed ID: 30548045
[TBL] [Abstract][Full Text] [Related]
35. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic application of the CRISPR system: current issues and new prospects.
Lee M; Kim H
Hum Genet; 2019 Jun; 138(6):563-590. PubMed ID: 31115652
[TBL] [Abstract][Full Text] [Related]
37. Tumor microenvironment based stimuli-responsive CRISPR/Cas delivery systems: A viable platform for interventional approaches.
Tang N; Ning Q; Wang Z; Tao Y; Zhao X; Tang S
Colloids Surf B Biointerfaces; 2022 Feb; 210():112257. PubMed ID: 34894597
[TBL] [Abstract][Full Text] [Related]
38. Advances in CRISPR Delivery Methods: Perspectives and Challenges.
Demirci S; Essawi K; Germino-Watnick P; Liu X; Hakami W; Tisdale JF
CRISPR J; 2022 Oct; 5(5):660-676. PubMed ID: 36260301
[TBL] [Abstract][Full Text] [Related]
39. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
Pei WD; Zhang Y; Yin TL; Yu Y
Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
